Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.68 |
| ▸ | AKR1C1 | Q04828 | 4/20 | 0.68 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.68 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30493211 | 0.91 | ALDH1A1 (0.83) | ALDH1A1HTTMEN1POLBKMT2A | |
| SCHEMBL3802490 | 0.85 | AKR1C3 (0.68) | ALDH1A1HTTMEN1POLBKMT2A | |
| SCHEMBL13347271 | 0.85 | AKR1C3 (0.68) | ALDH1A1HTTMEN1POLBKMT2A | |
| SCHEMBL3802491 | 0.85 | AKR1C3 (0.68) | ALDH1A1HTTMEN1POLBKMT2A | |
| SCHEMBL12485905 | 0.84 | MEN1 (0.81) | ALDH1A1HTTMEN1POLBKMT2A | |
| SCHEMBL12485904 | 0.84 | MEN1 (0.81) | ALDH1A1HTTMEN1POLBKMT2A | |
| SCHEMBL9125576 | 0.84 | AKR1C1 (0.75) | ALDH1A1HTTMEN1POLBKMT2A | |
| SCHEMBL9125567 | 0.84 | AKR1C1 (0.75) | ALDH1A1HTTMEN1POLBKMT2A | |
| SCHEMBL22510926 | 0.83 | ALDH1A1 (1.00) | ALDH1A1HTTMEN1POLBKMT2A | |
| SCHEMBL3040559 | 0.83 | AKR1C3 (0.75) | ALDH1A1HTTMEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060128702-A1 | Heterocyclic and bicyclic compounds, compositions and methods | REDDY US THERAPEUTICS, INC. | 2006-06-15 | — | — | US | disclosed |
| WO-2006058201-A2 | HETEROCYCLIC AND BICYCLIC COMPOUNDS, COMPOSITIONS AND METHODS | REDDY US THERAPEUTICS, INC. (US) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128702-A1 | Heterocyclic and bicyclic compounds, compositions and methods | HPSE, ENGASE, UGCG | ALDH1A1 2033/4885HTT 780/4885MEN1 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.